Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | BTK | Q06187 | 3/20 | 0.56 |
| ▸ | SYK | P43405 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475802 | 0.94 | JAK3 (0.60) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2473715 | 0.91 | JAK3 (0.64) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2474134 | 0.91 | EGFR (0.52) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2471097 | 0.90 | CDK2 (0.56) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2471442 | 0.90 | NTRK1 (0.64) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2477119 | 0.90 | NTRK1 (0.57) | JAK3PTK2EGFRSYKCDK2 | |
| SCHEMBL17685281 | 0.88 | JAK3 (0.56) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL14053146 | 0.88 | NTRK1 (0.54) | JAK3PTK2EGFRSYKCDK2 | |
| SCHEMBL4971147 | 0.86 | JAK3 (0.56) | JAK3PTK2EGFRBTKSYK | |
| SCHEMBL2472009 | 0.83 | NTRK1 (0.67) | JAK3PTK2EGFRBTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | claimed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2370415-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2011-10-05 | — | — | EP | claimed |
| WO-2010075558-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2370415-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8420659-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Riger Pharmaceuticals, Inc. | 2012-11-29 | — | — | US | disclosed |
| US-8268851-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158921-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885PTK2 468/4885EGFR 529/4885 |
| US-20120301486-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK3 1/4885PTK2 468/4885EGFR 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.